Fusen Pharmaceutical Company Ltd. has announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited, has received approval from the National Medical Products Administration of the PRC for the marketing of its "Compound Potassium Hydrogen Phosphate Injection." This new-generation phosphate supplement is intended for use in adult and pediatric patients requiring parenteral nutrition or treatment for hypophosphatemia, particularly when oral or enteral supplementation is not suitable. The approval is expected to expand the company's product pipeline in the therapeutic area of nutritional supplements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fusen Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968234), on December 29, 2025, and is solely responsible for the information contained therein.